[雨果診療室] 免疫及標靶藥物整理

引用自Harrison’s Priciple of Internal Medicine 17th edition

免疫藥物：

Name	Mechanism
Entanercept	TNF type II receptor fused to IgG1
Infliximab	chimeric mouse/human monoclonal antibody to TNF
adalimumab	fully human antibody to TNF
Anakinra	recombinant IL-1 receptor antagonist that competitively blocks the binding of IL-1β and IL-1α to the IL-1 receptor and thereby inhibits the activity of these two related proinflammatory cytokines
Rituximab	a chimeric antibody directed to CD20 that depletes mature B cells
batacept	A is a fusion protein consisting of CTLA4 and the Fc portion of IgG1. It inhibits T cell activation by competitively inhibiting the co-stimulation of T cellsthat results from interaction of T cell–expressed CD28 and CD80/86 expressed by antigen-presenting cells.

標靶藥物：

Name	Mehanism	Indication
All-trans retinoic acid(ATRA)	PML-RARα oncogene	Acute promyelocytic leukemia M3 AML; t(15;17)
Imatinib (Gleevec)	Bcr-Abl, c-Abl, c-Kit, PDGFR-α/β,	Chronic myelogenous leukemia; GIST
Sunitinib (Sutent)	c-Kit, VEGFR-2, PDGFR-β, Flt-3	GIST; renal cell cancer
Sorafinib (Nexavar)	RAF, VEGFR-2, PDGFR-α/β, Flt-3, c-Kit	RCC; may have activity in melanoma when combined with chemotherapy
Erlotinib (Tarceva)	EGFR Tki	Non-small cell lung cancer; pancreatic cancer
Gefitinb (Iressa)	EGFR Tki	Non-small cell lung cancer
Bortezomib (Velcade)	Proteasome	Multiple myeloma
		以下為Monoclonal Antibodies
Trastuzumab (Herceptin)	HER2/neu (ERBB2)	Breast cancer
Cetuximab (Erbitux)	EGFR	Colon cancer, squamous cell carcinoma of the head and neck
Panitumomab (Vectibix)	EGFR	Colon cancer
Rituximab (Rituxan)	CD20	B cell lymphomas and leukemias that express CD20
Alemtuzumab (Campath)	CD52	Chronic lymphocytic leukemia and CD52-expressing lymphoid tumors
Bevacizumab (Avastin)	VEGF	Colon, lung, breast cancers; data pending in other tumors

要看中文版的這篇還不錯：http://www.raag.org.tw/menu4_1.php?a_id=63